Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medivir AB ( (SE:MVIR) ) has shared an announcement.
Medivir AB has announced a fully guaranteed rights issue of approximately SEK 151 million, subject to approval at an extraordinary general meeting. The funds will primarily support a clinical study to demonstrate the efficacy of its drug candidate Fostrox in combination with lenvatinib. The rights issue is fully secured through subscription undertakings and guarantee commitments, ensuring financial backing for the company’s strategic development plans.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir is a pharmaceutical company focused on developing innovative treatments, with a particular emphasis on advancing drug candidates through clinical trials.
Average Trading Volume: 215,661
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK159.7M
See more insights into MVIR stock on TipRanks’ Stock Analysis page.